# Triodos & Investment Management

# KONINKLIJKE (ROYAL) PHILIPS NV

MEETING DATE	Fri, 19 Oct 2018 9:30 am	TYPE	EGM	ISSUE DATE	Mon, 08 Oct 2018
MEETING LOCATION	Hilton Amsterdam Hotel, Apollolaan 138, Am				
CURRENT INDICES	FTSE EuroFirst				
SECTOR	Electrical Components & Equipment				

#### COMPANY OVERVIEW

Koninklijke Philips N.V. is a Dutch diversified technology company. It provides healthcare and lighting technologies including cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

#### **MEETING SPECIFIC INFORMATION**

## Quorum requirements and voting majorities

No quorum required for ordinary resolutions at this meeting. Resolutions under ordinary business are approved by simple majority of the votes cast.

Special resolutions require a quorum of 50% of the share capital and are approved by majority of 66% of the votes cast.

	PROPOSALS	ADVICE
1	Elect A. Marc Harrison	For
	Independent Non-Executive Director.	

#### 2 Approve Fees Payable to the Board of Directors

**Abstain** 

It is proposed to increase the amount payable to the Board of Directors by more than 10% on annual basis. The increase is considered material and exceeds guidelines, but the Company has duly justified it: they have demonstrated consultation with external parties and have taken into account shareholder views. In 2017, the proposal of a 25% increase was withdrawn from the meeting agenda. As such, last increase was proposed in 2015, so in 2018 it is still considered within guidelines for increases of board fees (up to 10% per year per director, on average). Lastly, the Company has disclosed the peer companies and their remuneration is within the median.

Triodos supports an increase in Director's remuneration, but do not agree with Philips' aim to be in line with the median of the peer group. This type of increase continuously drives remuneration up. Besides, Triodos considers the peer group not appropriate.

# **BOARD AND COMMITTEE COMPOSITION (post-Meeting)**

#### **BOARD CHANGES**

Mr. Harrison will join the board after the meeting.

	INDEPENDENT BY								
DIRECTOR	GENDER	PIRC	COMPANY	BOARD	AC	RC	NC	SC	TENURE
Jeroen van der Veer	М	No	Yes	Ch	-	М	С	-	9
Christine Poon	F	No	Yes	VCh	-	М	М	-	9
Heino von Prondzynski	M	No	Yes	NED	-	С	М	-	11
Jackson Tai	M	Yes	Yes	NED	С	-	-	-	7
Neelam Dhawan	F	Yes	Yes	NED	М	-	-	-	6
Orit Gadiesh	F	Yes	Yes	NED	М	-	-	-	4
David Pyott	M	Yes	Yes	NED	М	-	-	-	3
Paul Stoffels	M	Yes	Yes	NED	-	-	-	-	<1
A. Marc Harrison	М	Yes	Yes	NED	-	-	-	-	<1
Number of Meetings									

Number of NED only Meetings

PIRC assesses a non-executive director's independence according to PIRC's shareholder guidelines. Comments represent PIRC's analysis based on information in the report and accounts. AC = Audit Committee, RC = Remuneration Committee, NC = Nomination Committee, SC = Sustainability Committee, C = Chairperson of Committee, M = Member of Committee.

# **BOARD OF DIRECTORS (post-Meeting)**

JEROEN VAN DER VEER				CHAIRMAN	(NON EXECUTIVE)	
AGE	71	TENURE	9 Years	COMMITTEES	R,N*	
OTHER POSITION	•	[Ch]; Mazarine	Energy B.V. [Adv];	ology [Ch]; Het Cond Royal Boskalis Westr	•	
INDEPENDENT BY PIRC	N		INDEPENDEN	T BY COMPANY	Υ	
COMMENT			ng to a tenure of or time commitment	ver nine years. There s.	are concerns over	
CHRISTINE POON				VICE CHAIRMAN	I (NON EXECUTIVE)	
AGE	66	TENURE	9 Years	COMMITTEES	R,N	
OTHER POSITION	-		-	illiams [NED]; ex-Jol armaceuticals Group		
INDEPENDENT BY PIRC	N		INDEPENDEN	T BY COMPANY	Υ	
COMMENT	Not considered i	ndependent owi	ng to a tenure of o	ver nine years.		
HEINO VON PRONDZYNS	KI			NON-EXE	CUTIVE DIRECTOR	
AGE	69	TENURE	11 Years	COMMITTEES	R*,N	
OTHER POSITION	Epigenomics AG [Ch]; HTL Strefa [NED]; Quotient Ltd. [SID]; ex-F. Hofmann- La Roche Group [Exec]; ex-Hospira [NED]; ex-Qiagen [NED]; ex-Roche Diagnostics [CEO]					
INDEPENDENT BY PIRC	N		INDEPENDEN	T BY COMPANY	Υ	
COMMENT	Not considered i	ndependent owi	ng to a tenure of o	ver nine years.		

JACKSON TAI					
				NON-EXE	CUTIVE DIRECTOR
AGE	67	TENURE	7 Years	COMMITTEES	A*
OTHER POSITION	Holdings PLC [NED]; ex-DBS B	IED]; MasterCard ank Ltd [VCh, CE ]; ex-Singapore <i>I</i>	I Incorporated [O]; ex-DBS Gro	Eli Lilly and Compa [NED]; Russell Regoup [VCh, CEO]; ex ex-The Bank of Chi	ynolds Associates -J.P. Morgan &Co
INDEPENDENT BY PIRC	Υ		INDEPENDENT	BY COMPANY	Υ
COMMENT	There are concern	ns over his potenti	al aggregate tim	e commitments.	
NEELAM DHAWAN				NON-EXE	CUTIVE DIRECTO
AGE	59	TENURE	6 Years	COMMITTEES	Α
OTHER POSITION	ICICI Bank Limite	d [NED]; ex-Hewle	ett-Packard India	[VP]	
INDEPENDENT BY PIRC	Υ		INDEPENDENT	BY COMPANY	Υ
ORIT GADIESH				NON-EXE	CUTIVE DIRECTO
AGE	67	TENURE	4 Years	COMMITTEES	A
OTHER POSITION	[Mem]; World Ec ex-British-America	onomic Forum [Nan Business Cour	/lem]; ex-Atlantionicil [Adv]; ex-Inte	States Council of C Council of the Urernational Business ex-RMAGRenova [NE	nited States [Adv Leaders' Advisor
INDEPENDENT BY PIRC	Υ		INDEPENDENT	BY COMPANY	Υ
DAVID PYOTT				NON-EXE	CUTIVE DIRECTO
AGE	65	TENURE	3 Years	COMMITTEES	A
	Alnylam Pharmac Corporation [SID Chapman Univers [Adv]; Governing	euticals Inc. [NED]; BioMarin Pharisity [Trustee]; Fou Board of the Lor bundation [Pres];	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut	COMMITTEES naceuticals Inc. [NEI] [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame	D]; Avery Dennison erapeutics [NED] of Ophthalmolog national Council of
OTHER POSITION	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology Fo	euticals Inc. [NED]; BioMarin Pharisity [Trustee]; Fou Board of the Lor bundation [Pres];	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut	naceuticals Inc. [NEI [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame	D]; Avery Dennison erapeutics [NED] of Ophthalmolog national Council of
OTHER POSITION  INDEPENDENT BY PIRC	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [A	euticals Inc. [NED ]; BioMarin Phar sity [Trustee]; Fou Board of the Lor oundation [Pres]; dv]; ex-Allergan, I	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut Inc [Ch & CEO]	naceuticals Inc. [NEI [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame	D]; Avery Dennison erapeutics [NED] of Ophthalmologi national Council of erican Academy of
OTHER POSITION  INDEPENDENT BY PIRC  COMMENT	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [A	euticals Inc. [NED ]; BioMarin Phar sity [Trustee]; Fou Board of the Lor oundation [Pres]; dv]; ex-Allergan, I	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut Inc [Ch & CEO]	naceuticals Inc. [NEI [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame	D]; Avery Dennison erapeutics [NED] of Ophthalmologi national Council of erican Academy of
OTHER POSITION  INDEPENDENT BY PIRC COMMENT  PAUL STOFFELS	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [A	euticals Inc. [NED ]; BioMarin Phar sity [Trustee]; Fou Board of the Lor oundation [Pres]; dv]; ex-Allergan, I	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut Inc [Ch & CEO]	naceuticals Inc. [NEI [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame	D]; Avery Dennison erapeutics [NED] of Ophthalmologinational Council or crican Academy of Y
OTHER POSITION  INDEPENDENT BY PIRC COMMENT  PAUL STOFFELS  AGE	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [A Y There are concern	euticals Inc. [NED]; BioMarin Pharisity [Trustee]; Fou Board of the Loroundation [Pres]; dv]; ex-Allergan, I has over the directo	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut Inc [Ch & CEO] INDEPENDENT I's potential aggi	naceuticals Inc. [NEI [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame BY COMPANY regate time commite NON-EXE	D]; Avery Dennisonerapeutics [NED] of Ophthalmolognational Council orican Academy of Prican Academy of Councils.
OTHER POSITION  INDEPENDENT BY PIRC COMMENT  PAUL STOFFELS  AGE OTHER POSITION	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [A Y There are concern	euticals Inc. [NED]; BioMarin Pharisity [Trustee]; Fou Board of the Loroundation [Pres]; dv]; ex-Allergan, I has over the directo	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut Inc [Ch & CEO] INDEPENDENT I's potential aggi	naceuticals Inc. [NEI [NED]; Bioniz Th American Academy School [Mem]; Interritics [NED]; the Ame BY COMPANY regate time commitm NON-EXE COMMITTEES	D]; Avery Dennisonerapeutics [NED] of Ophthalmolognational Council orican Academy of Prican Academy of Councils.
INDEPENDENT BY PIRC COMMENT  PAUL STOFFELS  AGE OTHER POSITION INDEPENDENT BY PIRC	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [And Yang Pharmac There are concernated by the	euticals Inc. [NED]; BioMarin Pharisity [Trustee]; Fou Board of the Loroundation [Pres]; dv]; ex-Allergan, I has over the directo	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut Inc [Ch & CEO] INDEPENDENT In's potential aggination of the A Inc [Ch]; ex-Virco	naceuticals Inc. [NEI] [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame BY COMPANY regate time commitm  NON-EXE  COMMITTEES [CEO] BY COMPANY	D]; Avery Dennison erapeutics [NED] of Ophthalmolog national Council of crican Academy of Y nents.  CUTIVE DIRECTO None
INDEPENDENT BY PIRC COMMENT  PAUL STOFFELS  AGE OTHER POSITION INDEPENDENT BY PIRC  A. MARC HARRISON	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [A Y There are concernated 56 Johnson & Johnson	euticals Inc. [NED]; BioMarin Pharisity [Trustee]; Fou Board of the Loroundation [Pres]; dv]; ex-Allergan, Ins over the director TENURE on [Exec]; ex-Tiote	]; Alnylam Pharm maceutical Inc. Indation of the A Indon Business S Rani Therapeut Inc [Ch & CEO] INDEPENDENT INDEPENDENT <1 Years EC [Ch]; ex-Virco	naceuticals Inc. [NEI [NED]; Bioniz Th American Academy School [Mem]; Interritics [NED]; the America [NED];	D]; Avery Dennisonerapeutics [NED] of Ophthalmolognational Council of Council
AGE OTHER POSITION  INDEPENDENT BY PIRC COMMENT  PAUL STOFFELS  AGE OTHER POSITION INDEPENDENT BY PIRC  A. MARC HARRISON  AGE OTHER POSITION	Alnylam Pharmac Corporation [SID] Chapman Univers [Adv]; Governing Ophthalmology For Ophthalmology [And Yang Pharmac There are concernated by the	euticals Inc. [NED]; BioMarin Pharisity [Trustee]; Fou Board of the Loroundation [Pres]; dv]; ex-Allergan, Ins over the director TENURE  TENURE  TENURE	]; Alnylam Pharm maceutical Inc. Indation of the A Idon Business S Rani Therapeut Inc [Ch & CEO] INDEPENDENT INTERIOR S INDEPENDENT INDEPENDENT INDEPENDENT  <1 Years  <1 Years  <1 Years	naceuticals Inc. [NEI] [NED]; Bioniz Th American Academy School [Mem]; Interr tics [NED]; the Ame BY COMPANY regate time commitm  NON-EXE  COMMITTEES [CEO] BY COMPANY	D]; Avery Dennisor erapeutics [NED] of Ophthalmology national Council of rican Academy of Y nents.  CUTIVE DIRECTO None

# **BOARD COMPOSITION**

## **BOARD COMPOSITION FOLLOWING THE EGM**

			FTSE EUROFIRST MEAN		
	Number	% of Board	Number	% of Board	
Executive Director	0	0.0	1.5	11.8	
Independent NEDs	6	66.67	5.0	40.1	
Connected NEDs	3	33.33	4.2	33.5	
Other	0	0.0	1.8	14.3	

## **BOARD COMMITTEES FOLLOWING THE EGM**

					FTSE EUROFIRST MEAN		
	Number of Members	% Women	% Independent by PIRC	% Independent by Company	Number of Members	% Independent by PIRC	
Whole Board	9	33.33	66.67	100.0	12.4	42.4	
Audit	4	50.0	100.0	100.0	4.0	57.7	
Remuneration	3	33.33	0.0	100.0	3.6	52.4	
Nomination	3	33.33	0.0	100.0	4.1	51.3	

## For Private Circulation only

© Copyright 2018 PIRC Ltd

Researcher: Ahmed Suliman Email: pircresearch@pirc.co.uk

Information is believed to be correct but cannot be guaranteed. Opinions and recommendations constitute our judgement as of this date and are subject to change without notice. The document is not intended as an offer, solicitation or advice to buy or sell securities. Clients of Pensions & Investment Research Consultants Ltd may have a position or engage in transaction in any of the securities mentioned.



Pensions & Investment Research Consultants Limited 8th Floor, Suite 8.02, Exchange Tower 2 Harbour Exchange Square E14 9GE

> Tel: 020 7247 2323 Fax: 020 7247 2457 http://www.pirc.co.uk

**Regulated by the Financial Conduct Authority**